权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

THYROID ANTIBODIES AS A RISK FACTOR FOR TRISOMY BIRTHS

甲状腺抗体是三体出生的危险因素

基本信息

批准号：
3319872
负责人：
BARBARA J VAN DEN BERG
金额：
$ 11.39万
依托单位：
UNIVERSITY OF CALIFORNIA BERKELEY
依托单位国家：
美国
项目类别：
财政年份：
1987
资助国家：
美国
起止时间：
1987-03-01 至 1988-10-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/3319872
关键词：
Downs syndrome amniocentesis antibody child mental disorders disease /disorder proneness /risk epidemiology hemagglutination test human subject immunogenetics immunopathology longitudinal human study radioimmunoassay trisomy

项目摘要

There is a body of epidemiologic evidence that has associated the birth of children with Down's syndrome or with other trisomies with the presence of thyroid antibodies in the serum of those children's parents. Cases for such studies were selected from children or adults with the syndromes who had survived the earliest years of life. If thyroid antibodies are a risk factor for chromosomal non-disjunction, then those antibodies should be present in a parent at the time of conception; otherwise the association could be due to selection bias for survivors whose altered immune system could be protective. We will test the hypothesis of an association of thyroid antibodies with trisomy births in a case-control study in which all cases and controls were ascertained at birth and all parental sera were drawn at the beginning of the pregnancy and stored for future research. 115 cases have been identified from the records of two large longitudinal studies, the Child Health and Development Study (CHDS) and the Collaborative Perinatal Project (CPP), with some 20,000 and 50,000 births respectively. Three controls per case will be selected from the same populations and matched for age and race of the mother and the father. Parental sera will be tested for thyroid antibodies. If this association is verified, it could have important public health implications because, at this time, there are no known risk factors other than age for the identification of mothers at risk of a trisomy birth. Although the incidence of DS is 10 to 100 times greater in women 35 to 45 years of age, the majority of DS are born to younger mothers for whom, as a group, amniocentesis would not be cost or risk effective. A test for thyroid antibodies is inexpensive and without risk to the mother-child pair. Mothers who were positive could then be tested by other means such as amniocentesis. This study design offers the unique opportunity to test this important hypothesis at a minimum of cost because the needed records and bloods are already available for analysis.

有大量流行病学证据表明出生患有唐氏综合症或其他三体症的儿童那些人的血清中存在甲状腺抗体孩子的父母。此类研究的案例选自幸存下来的患有综合症的儿童或成人生命最早的岁月。如果甲状腺抗体是一个危险因素染色体不分离，那么这些抗体应该是受孕时存在于父母体内；否则关联可能是由于对幸存者的选择偏差改变的免疫系统可能具有保护作用。我们将检验甲状腺抗体关联的假设病例对照研究中的三体性出生，其中所有病例和出生时确定对照，所有亲代血清均已检测在怀孕初期绘制并保存以供将来使用研究。两家公司的记录中已查明 115 起案件大型纵向研究，儿童健康与发展研究 (CHDS) 和围产期合作项目 (CPP)，分别有约 20,000 和 50,000 名新生儿出生。每三个控制病例将从相同人群中选择并进行匹配母亲和父亲的年龄和种族。亲代血清将是检测甲状腺抗体。如果这个协会得到证实，它可能会产生重要的公众影响健康影响，因为目前尚无已知风险除了年龄以外，还需要考虑其他因素来确定母亲是否有患上这种疾病的风险三体性出生。虽然DS的发生率是DS的10到100倍 35 至 45 岁的女性中，大多数 DS 是年轻母亲所生的孩子，作为一个群体，接受羊膜穿刺术不会具有成本效益或风险效益。甲状腺抗体测试成本低廉，而且对母子没有风险。母亲们然后可以通过其他方式对呈阳性的人进行测试，例如羊膜穿刺术。这项研究设计提供了独特的机会以最小的成本检验这个重要的假设，因为所需的记录和血液已经可供分析。